Funding
Etubics has brought their technology from "bench to bedside" on under $3 million. These accomplishments have been made on minimal investments from both investors and non-dilutive grants to Etubics, as detailed below.
Financing of Etubics and its underlying technology from inception to date has been accomplished through investments from individuals close to the company, its insiders and previous and current competitive National Institutes of Health (NIH) grants and contracts totaling millions. Of this, the majority has been, or is being, invested through non-dilutive grants to produce the basic research of the techcnology and move the first product to clinical trials for the treatment of colon cancers.
Etubics has both competitive peer-reviewed grants and contracts from:
National Cancer Institute (NCI)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Health (NIH)
Select grants Etubics has recieved are below.
Non-Dilutive National Institute of Health Grants
| Disease | Agency | |
| HIV | ||
| SBIR Stage 1 |
NIAID | |
| SBIR Stage 2 |
NIAID | |
| RO3 |
NIAID | |
| Colon Cancer (CEA) | ||
| SBIR Stage 1 |
NCI | |
| SBIR Stage 2 |
NCI | |
| SBIR Manufacturing Contract |
NCI | |
| Breast Cancer | ||
| HER2neu SBIR Stage 1 |
NCI | |
| Equine Encephalitis Virus (VEEV) | ||
| Regional Centers of Excellence |
NIAID | |